SELLAS Life Sciences Group (SLS) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free SLS Stock Alerts $1.56 -0.07 (-4.23%) (As of 01:45 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payoutseekingalpha.com - April 19 at 3:11 PMSELLAS Life Sciences Group files for $200M mixed shelfmsn.com - March 28 at 7:32 PMSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 28 at 4:05 PMBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financialsmarkets.businessinsider.com - March 27 at 10:54 PMSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Studymarkets.businessinsider.com - March 26 at 10:33 AMSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Studyglobenewswire.com - March 26 at 7:35 AMSELLAS Life Sciences Group Inc.wsj.com - March 21 at 3:15 PMSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 19 at 4:05 PMSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETglobenewswire.com - March 19 at 8:47 AMSellas Life Sciences Shares Drop 31% After Direct Offering Pricesmarketwatch.com - March 16 at 2:16 PMGeron, Graphite Bio, Immuneering among healthcare moversmsn.com - March 15 at 10:20 AMSELLAS Life Sciences looks to raise $20M in a direct offeringmsn.com - March 15 at 10:20 AMSellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placementmarkets.businessinsider.com - March 15 at 10:20 AMSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - March 15 at 9:14 AMSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 15 at 9:00 AMAadi Bioscience Q4 2023 Earnings Previewseekingalpha.com - March 12 at 12:49 PMSellas Life Sciences Group Inc (SLS)investing.com - March 10 at 5:06 AMSELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnershipsfinanznachrichten.de - March 9 at 3:43 PMSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnershipsglobenewswire.com - March 8 at 8:00 AMSLS Mar 2024 4.000 putfinance.yahoo.com - March 7 at 11:22 PMSELLAS Life Sciences Group, Inc. (SLS)finance.yahoo.com - March 1 at 3:52 PMSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conferenceglobenewswire.com - March 1 at 8:30 AMSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Timeglobenewswire.com - February 29 at 8:00 AMSELLAS Life Sciences Group Incmorningstar.com - February 22 at 1:53 PMSLS Feb 2024 0.500 callca.finance.yahoo.com - February 16 at 12:21 AMSELLAS Life Sciences Group, Inc.: SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotargetfinanznachrichten.de - February 6 at 1:04 PMSELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotargetfinance.yahoo.com - February 6 at 8:48 AMTesla sued for allegedly mishandling hazardous waste in California for yearsnews.yahoo.com - February 1 at 8:02 PMSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conferencefinance.yahoo.com - January 25 at 9:04 AMSellas Life Sciences gains on securing orphan drug status for r/r PTCL treatmentmsn.com - January 11 at 8:16 AMBuy Rating Affirmed for SELLAS Life Sciences Amidst Promising Drug Development and Strategic Financingmarkets.businessinsider.com - January 10 at 6:13 PMSellas Life Sciences gains after leukemia therapy gets FDA fast track statusmsn.com - January 9 at 10:22 AMSELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patientsfinance.yahoo.com - January 9 at 8:45 AMSELLAS Life Sciences Prices Share Offering To Raise $9 Mln; Stock Tanks 35%markets.businessinsider.com - January 4 at 1:48 PMSELLAS Life Sciences Announces Pricing of $9.0 Million Public Offeringfinance.yahoo.com - January 4 at 9:29 AMWhy Is Sellas Life Sciences (SLS) Stock Down 25% Today?msn.com - January 4 at 8:47 AMSELLAS Life Sciences announces launch of proposed public offeringmsn.com - January 4 at 5:12 AMSELLAS Life Sciences Reports Proposed Public Offeringmarkets.businessinsider.com - January 3 at 11:05 PMSELLAS Life Sciences Group, Inc.: SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestonesfinanznachrichten.de - January 3 at 12:28 PMSELLAS provides corporate updates, shares up premarketmsn.com - January 3 at 12:28 PMSELLAS Provides Corporate Updates and Highlights Key Upcoming Milestonesfinance.yahoo.com - January 3 at 8:04 AMSELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesotheliomafinance.yahoo.com - December 27 at 9:27 AMSELLAS Life Sciences Group, Inc.: SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomasfinanznachrichten.de - December 21 at 10:53 AMSellas Life Sciences Group Receives Orphan Drug Designation For SLS009 For Treatment Of PTCLmarkets.businessinsider.com - December 21 at 10:53 AMSELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomasfinance.yahoo.com - December 21 at 10:52 AMSELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemiafinance.yahoo.com - December 14 at 9:25 AMSELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ETfinance.yahoo.com - December 13 at 8:44 AMSELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemiafinance.yahoo.com - December 4 at 9:06 AMAnalysts’ Top Healthcare Picks: Olema Pharmaceuticals (OLMA), SELLAS Life Sciences Group (SLS)markets.businessinsider.com - December 1 at 12:22 AMSELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemiafinance.yahoo.com - November 29 at 10:41 AM Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. SLS Media Mentions By Week SLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLS News Sentiment▼0.000.44▲Average Medical News Sentiment SLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLS Articles This Week▼11▲SLS Articles Average Week Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DiaMedica Therapeutics News Allakos News BioXcel Therapeutics News PMV Pharmaceuticals News Milestone Pharmaceuticals News ProPhase Labs News Abeona Therapeutics News Genelux News BeyondSpring News Oramed Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
